image
Healthcare - Medical - Devices - NASDAQ - US
$ 10.93
-2.76 %
$ 302 M
Market Cap
-15.84
P/E
1. INTRINSIC VALUE

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco.[ Read More ]

The intrinsic value of one CLPT stock under the base case scenario is HIDDEN Compared to the current market price of 10.9 USD, ClearPoint Neuro, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CLPT

image
FINANCIALS
24 M REVENUE
16.56%
-22.4 M OPERATING INCOME
-37.44%
-22.1 M NET INCOME
-34.40%
-13.7 M OPERATING CASH FLOW
15.14%
8.95 M INVESTING CASH FLOW
183.36%
296 K FINANCING CASH FLOW
-27.63%
8.12 M REVENUE
3.36%
-5.17 M OPERATING INCOME
-9.14%
-4.97 M NET INCOME
-12.84%
-1.2 M OPERATING CASH FLOW
55.06%
-12 K INVESTING CASH FLOW
0.00%
-10.1 M FINANCING CASH FLOW
-6288.12%
Balance Sheet Decomposition ClearPoint Neuro, Inc.
image
Current Assets 36.2 M
Cash & Short-Term Investments 23.1 M
Receivables 3.94 M
Other Current Assets 9.09 M
Non-Current Assets 6.49 M
Long-Term Investments 0
PP&E 4.95 M
Other Non-Current Assets 1.54 M
Current Liabilities 7.43 M
Accounts Payable 393 K
Short-Term Debt 848 K
Other Current Liabilities 6.19 M
Non-Current Liabilities 14.1 M
Long-Term Debt 13.5 M
Other Non-Current Liabilities 541 K
EFFICIENCY
Earnings Waterfall ClearPoint Neuro, Inc.
image
Revenue 24 M
Cost Of Revenue 10.3 M
Gross Profit 13.6 M
Operating Expenses 36.1 M
Operating Income -22.4 M
Other Expenses -357 K
Net Income -22.1 M
RATIOS
56.83% GROSS MARGIN
56.83%
-93.70% OPERATING MARGIN
-93.70%
-92.21% NET MARGIN
-92.21%
-104.33% ROE
-104.33%
-51.78% ROA
-51.78%
-71.15% ROIC
-71.15%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ClearPoint Neuro, Inc.
image
Net Income -22.1 M
Depreciation & Amortization 1.46 M
Capital Expenditures -1.05 M
Stock-Based Compensation 6.08 M
Change in Working Capital -356 K
Others 2.04 M
Free Cash Flow -14.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ClearPoint Neuro, Inc.
image
Wall Street analysts predict an average 1-year price target for CLPT of $12 , with forecasts ranging from a low of $9 to a high of $15 .
CLPT Lowest Price Target Wall Street Target
9 USD -17.66%
CLPT Average Price Target Wall Street Target
12 USD 9.79%
CLPT Highest Price Target Wall Street Target
15 USD 37.24%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership ClearPoint Neuro, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 years ago
Aug 15, 2022
Sell 303 K USD
BURNETT JOSEPH MICHAEL
CEO and President
- 18867
16.07 USD
3 years ago
Nov 11, 2021
Sell 169 K USD
BURNETT JOSEPH MICHAEL
CEO and President
- 10000
16.88 USD
3 years ago
Sep 21, 2021
Sell 173 K USD
BURNETT JOSEPH MICHAEL
CEO and President
- 9637
17.98 USD
3 years ago
Jun 21, 2021
Sell 464 K USD
BURNETT JOSEPH MICHAEL
CEO and President
- 25000
18.57 USD
6 years ago
Sep 25, 2018
Bought 31.2 K USD
BURNETT JOSEPH MICHAEL
President and CEO
+ 25000
1.25 USD
6 years ago
Aug 24, 2018
Bought 11.8 K USD
BURNETT JOSEPH MICHAEL
President and CEO
+ 7500
1.58 USD
6 years ago
Aug 22, 2018
Bought 7.19 K USD
BURNETT JOSEPH MICHAEL
President and CEO
+ 4637
1.55 USD
6 years ago
May 21, 2018
Bought 17.9 K USD
BURNETT JOSEPH MICHAEL
President and CEO
+ 7500
2.387 USD
7 years ago
May 26, 2017
Bought 15 K USD
Jenkins Kimble L.
Director
+ 7500
2 USD
7 years ago
May 26, 2017
Bought 16.5 K USD
Jenkins Kimble L.
Director
+ 7500
2.2 USD
7 years ago
May 26, 2017
Bought 25 K USD
Grillo Francis P
CHIEF EXECUTIVE OFFICER
+ 12500
2 USD
7 years ago
May 26, 2017
Bought 27.5 K USD
Grillo Francis P
CHIEF EXECUTIVE OFFICER
+ 12500
2.2 USD
8 years ago
Sep 02, 2016
Bought 50 K USD
Rooke Andrew K.
Director
+ 10000
5 USD
8 years ago
Sep 02, 2016
Bought 49.5 K USD
Rooke Andrew K.
Director
+ 9000
5.5 USD
10 years ago
Mar 25, 2014
Bought 41.2 K USD
Rooke Andrew K.
Director
+ 7500
5.5 USD
8 years ago
Sep 02, 2016
Bought 100 K USD
Grillo Francis P
CHIEF EXECUTIVE OFFICER
+ 20000
5 USD
8 years ago
Sep 02, 2016
Bought 99 K USD
Grillo Francis P
CHIEF EXECUTIVE OFFICER
+ 18000
5.5 USD
8 years ago
Dec 18, 2015
Bought 100 K USD
Grillo Francis P
CHIEF EXECUTIVE OFFICER/PRES
+ 308071
0.3246 USD
8 years ago
Dec 18, 2015
Bought 50 K USD
Grillo Francis P
CHIEF EXECUTIVE OFFICER/PRES
+ 123229
0.4058 USD
8 years ago
Dec 18, 2015
Bought 48.8 K USD
Grillo Francis P
CHIEF EXECUTIVE OFFICER/PRES
+ 92422
0.5275 USD
8 years ago
Dec 18, 2015
Bought 50 K USD
KOOB CHARLES E
Director
+ 154035
0.3246 USD
8 years ago
Dec 18, 2015
Bought 25 K USD
KOOB CHARLES E
Director
+ 61614
0.4058 USD
8 years ago
Dec 18, 2015
Bought 24.4 K USD
KOOB CHARLES E
Director
+ 46211
0.5275 USD
8 years ago
Dec 18, 2015
Bought 50 K USD
Rooke Andrew K.
Director
+ 154035
0.3246 USD
8 years ago
Dec 18, 2015
Bought 25 K USD
Rooke Andrew K.
Director
+ 61614
0.4058 USD
8 years ago
Dec 18, 2015
Bought 24.4 K USD
Rooke Andrew K.
Director
+ 46211
0.5275 USD
8 years ago
Dec 18, 2015
Bought 25 K USD
Richards Timothy T.
Director
+ 77017
0.3246 USD
8 years ago
Dec 18, 2015
Bought 12.5 K USD
Richards Timothy T.
Director
+ 30807
0.4058 USD
8 years ago
Dec 18, 2015
Bought 12.2 K USD
Richards Timothy T.
Director
+ 23106
0.5275 USD
9 years ago
Dec 24, 2014
Bought 15 K USD
Sainz Maria
Director
+ 23310
0.6435 USD
9 years ago
Dec 24, 2014
Bought 8 K USD
Sainz Maria
Director
+ 9324
0.858 USD
10 years ago
Sep 12, 2014
Bought 11.8 K USD
SPENCER JOHN N JR
Director
+ 10000
1.18 USD
10 years ago
Sep 12, 2014
Bought 7.08 K USD
SPENCER JOHN N JR
Director
+ 6000
1.18 USD
10 years ago
Aug 13, 2014
Bought 3.5 K USD
SPENCER JOHN N JR
Director
+ 3500
1 USD
10 years ago
Jun 13, 2014
Bought 21.9 K USD
Rooke Andrew K.
director, 10 percent owner:
+ 30000
0.73 USD
10 years ago
Jun 10, 2014
Bought 39.2 K USD
Rooke Andrew K.
director, 10 percent owner:
+ 50000
0.7842 USD
10 years ago
Mar 25, 2014
Bought 52.5 K USD
PIETRANGELO MICHAEL
Director
+ 30000
1.75 USD
10 years ago
Mar 25, 2014
Bought 525 K USD
Rooke Andrew K.
director, 10 percent owner:
+ 300000
1.75 USD
11 years ago
Aug 19, 2013
Bought 127 K USD
PIETRANGELO MICHAEL
Director
+ 100000
1.27 USD
11 years ago
Jun 11, 2013
Bought 46 K USD
PIETRANGELO MICHAEL
Director
+ 41855
1.1 USD
11 years ago
May 13, 2013
Bought 1.98 K USD
SPENCER JOHN N JR
Director
+ 1500
1.32 USD
11 years ago
Mar 22, 2013
Bought 3.7 K USD
Conway Bruce C.
Director
+ 2500
1.48 USD
11 years ago
Mar 20, 2013
Bought 3.45 K USD
Conway Bruce C.
Director
+ 2300
1.5 USD
11 years ago
Mar 19, 2013
Bought 298 USD
Conway Bruce C.
Director
+ 200
1.49 USD
11 years ago
Mar 14, 2013
Bought 2.24 K USD
Conway Bruce C.
Director
+ 1500
1.49 USD
11 years ago
Mar 14, 2013
Bought 11.2 K USD
Conway Bruce C.
Director
+ 7500
1.5 USD
11 years ago
Mar 14, 2013
Bought 5.35 K USD
Conway Bruce C.
Director
+ 3665
1.46 USD
7. News
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. accesswire.com - 3 days ago
ClearPoint Neuro: Near-Term Volatility Is No Concern ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution. seekingalpha.com - 1 week ago
ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. seekingalpha.com - 1 week ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.20 per share a year ago. zacks.com - 1 week ago
ClearPoint Neuro Reports Third Quarter 2024 Results Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024. Third Quarter Highlights Reported quarterly revenue of $8.1 million, a 41% year-over-year increase; Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase; Overall product revenue, including biologics and drug delivery, more than doubled year-over-year, growing 127% to $5.5 million; Activated five new global centers in the third quarter for a total of 19 new centers so far this year; approximately three times our historic activation rate; Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications; Full early repayment of the principal amount and interest on a $10 million convertible note leaving the Company with no outstanding debt as of September 30, 2024; Quarterly operational cash burn reduced to $1.2 million, a 33% year-over-year decrease; and Reported cash and cash equivalents totaling $21.6 million as of September 30, 2024. accesswire.com - 1 week ago
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024 President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE. accesswire.com - 2 weeks ago
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024 SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. globenewswire.com - 1 month ago
ClearPoint Neuro (CLPT) Soars 6.9%: Is Further Upside Left in the Stock? ClearPoint Neuro (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 1 month ago
ClearPoint Neuro Announces Early Repayment of $10 Million Note ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics globenewswire.com - 2 months ago
ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade) ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to progress. This was highlighted recently by uniQure's solid clinical trial data. seekingalpha.com - 3 months ago
ClearPoint Neuro: My Favorite Growth Stock ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat by working with partners early in clinical work, making its products part of FDA submissions. Continuous growth is expected through partner programs, consulting fees, and possible royalties and milestone payments. seekingalpha.com - 3 months ago
ClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call Transcript ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Kyle Bauser - B. Riley Emily Christy - Stifel Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Second Quarter 2024 Financial Results Conference Call. seekingalpha.com - 3 months ago
8. Profile Summary

ClearPoint Neuro, Inc. CLPT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 302 M
Dividend Yield 0.00%
Description ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Contact 120 S. Sierra Avenue, Solana Beach, CA, 92075 https://www.clearpointneuro.com
IPO Date May 22, 2012
Employees 107
Officers Mr. Joseph Michael Burnett President, Chief Executive Officer & Director Mr. Danilo D'Alessandro Chief Financial Officer Mr. Jeremy Stigall Chief Business Officer Mr. Mazin Sabra Chief Operating Officer Ms. Jacqueline Keller Vice President of Marketing